Business & Industry News
Takeda's Investigational Compound TAK-536 Enters into Phase 2 Clinical Stage in Japan
Takeda Pharmaceutical Company Limited ("Takeda") announced that its investigational compound TAK-536 has entered into Phase 2 clinical stage in Japan. TAK-536 is an angiotensin receptor blocker (ARB) discovered by Takeda and its mechanism of action is to lower blood pressure by inhibiting action of a vasopressor hormone Angiotensin II. Results Were Consistent in Patients Switched to Angiox from Other Antithrombin Therapy
Patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), or angioplasty, experienced nearly 50 percent less bleeding at 30 days and comparable mortality at one-year when treated with Angiox(R) (bivalirudin) alone compared to unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor (GPI), according to data from the ACUITY trial. Strategic Acquisition of MedPointe Inc Completed
Award for Bilobil in Poland
Journalists from Argentina and Greece win Novo Nordisk Media Prize 2007
Journalists Gabriela Navarra from Argentina and Michael Kefalogiannis from Greece won the Novo Nordisk Media Prize 2007 for the best article in lay press and the best TV feature about diabetes, respectively. The awards were presented by the president and CEO of Novo Nordisk, Lars Rebien Sørensen, during a ceremony held on 28 August in Copenhagen. InferMed appoints Cancer Research UK's Dr Sally Burtles as Observer to the Board
InferMed has a long-standing relationship with Cancer Research UK, and was backed by the charity at its formation in 1999. A research relationship continues with Cancer Research UK, which remains InferMed's largest institutional shareholder.
More Pharma News ...
Business & Industry
- Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
- CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
- Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
- BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
- Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
Research & Development
- Candidate found to inhibit malignant melanoma growth
- A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
- 'Biohybrid' device could restore function in paralysed limbs
- Scientists use tardigrade proteins for human health breakthrough
- DNA treatment could delay paralysis that strikes nearly all patients with ALS
- Scientists reveal a potential new approach to treating liver cancer
- Normalizing tumor blood vessels may improve immunotherapy against brain cancer
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA grants Accelerated Approval for Alzheimer's disease treatment
- FDA approves new HIV drug for adults with limited treatment options
- FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
- FDA approves first gene therapy to treat adults with Hemophilia B
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease